Headlines

Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition

Published by Global Banking and Finance Review

Posted on April 18, 2025

Featured image for article about Headlines

(Reuters) -The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.

(Reporting by Christy Santhosh and Gnaneshwar Rajan in Bengaluru; Editing by Alison Williams)

;